In IDAC consolidation group (25 AML patients), 2, 8 and 2 patients had FLT3-ITD, NPM1 and CEBPA mutation, respectively and 13 patients had no gene mutation. This evidence concerns the gene NPM1 and acute myeloid leukemia.